Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.64 -0.28 (-0.97%)
Official Closing Price Updated: 7:00 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 26,145,873
Open 28.90
Bid (Size) 28.67 (4)
Ask (Size) 28.69 (9)
Prev. Close 28.92
Today's Range 28.51 - 28.91
52wk Range 25.20 - 40.37
Shares Outstanding 5,606,688,356
Dividend Yield 5.73%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Moderna wins a crucial legal battle at the European Patent Office against Pfizer and BioNTech over Covid-19 vaccine patents. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale
GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advil painkillers. 
Via Benzinga

Performance

YTD
-3.67%
-3.67%
1 Month
+12.67%
+12.67%
3 Month
+3.69%
+3.69%
6 Month
-4.28%
-4.28%
1 Year
-21.49%
-21.49%

More News

Read More
7 Value Stocks to Buy and Hold for a Decade of Dominance
Via InvestorPlace
Could Novavax Become the Next Moderna?
Via The Motley Fool
Which Is The Best Investment For You? High Yield Pfizer Or Higher Growth Merck?
Via Talk Markets
Spotlight on Pfizer: Analyzing the Surge in Options Activity
Via Benzinga
Is This a Setback for Moderna?
Via The Motley Fool
2 Top Growth Stocks Down 24% and 50% to Buy With $100
Via The Motley Fool
Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
Via Benzinga
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
From Arvinas Inc.
Via GlobeNewswire
Pfizer Settles Zantac Lawsuits, Agrees To $250M Settlement To Reduce Liability: Report
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'
Via Benzinga
Exposures COVID-19
7 Cheap Value Stocks to Buy Now: May 2024
Via InvestorPlace
3 No-Brainer Stocks to Buy With $500 Right Now
Via The Motley Fool
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Via Benzinga
Topics Cannabis
Exposures Cannabis
2 Healthcare Stocks to Buy and Hold for Great Long-Term Potential
Via The Motley Fool
Pfizer Follows Eli Lilly's Footsteps To Sell Medicines Directly To Patients
Via Benzinga
Exposures COVID-19
Generis Welcomes Max Kelleher as New Chief Executive Officer
Via PRLog
Healthcare Giants Pfizer, AstraZeneca, Sanofi Inject Over $2B To Boost France's Healthcare Sector
Via Benzinga
How Viking Therapeutics Stock Could 30x
Via The Motley Fool
3 Stocks That Suddenly Drew in Options Traders
Via MarketBeat
Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in Pfizer Stock
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.